Manejo de hemorragia asociada a anticoagulantes orales directos: estado actual de las estrategias de reversión

Direct oral anticoagulants (DOACs), including the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban have at least comparable efficacy as vitamin K antagonists along with a better safety profile, reflected by a lower incidence of intracranial...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Enríquez,Andrés, Baranchuk,Adrian, Corbalán,Ramón
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2019
Materias:	Anticoagulants Hemorrhage Risk Factors
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000100073
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872019000100073
record_format	dspace
spelling	oai:scielo:S0034-988720190001000732019-04-03Manejo de hemorragia asociada a anticoagulantes orales directos: estado actual de las estrategias de reversiónEnríquez,AndrésBaranchuk,AdrianCorbalán,Ramón Anticoagulants Hemorrhage Risk Factors Direct oral anticoagulants (DOACs), including the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban have at least comparable efficacy as vitamin K antagonists along with a better safety profile, reflected by a lower incidence of intracranial hemorrhage. Specific reversal agents have been developed in recent years. Namely, idarucizumab, a specific antidote for dabigatran, is currently approved in most countries. Andexanet, which reverses factor Xa inhibitors, has been recently approved by the FDA, and ciraparantag, a universal antidote targeted to reverse all DOACs, is still under investigation. In this review we provide an update on the pharmacology of DOACs, the risk of hemorrhagic complications associated with their use, the measurement of their anticoagulant effect and the reversal strategies in case of DOAC-associated bleeding.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.147 n.1 20192019-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000100073es10.4067/S0034-98872019000100073
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Anticoagulants Hemorrhage Risk Factors
spellingShingle	Anticoagulants Hemorrhage Risk Factors Enríquez,Andrés Baranchuk,Adrian Corbalán,Ramón Manejo de hemorragia asociada a anticoagulantes orales directos: estado actual de las estrategias de reversión
description	Direct oral anticoagulants (DOACs), including the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban have at least comparable efficacy as vitamin K antagonists along with a better safety profile, reflected by a lower incidence of intracranial hemorrhage. Specific reversal agents have been developed in recent years. Namely, idarucizumab, a specific antidote for dabigatran, is currently approved in most countries. Andexanet, which reverses factor Xa inhibitors, has been recently approved by the FDA, and ciraparantag, a universal antidote targeted to reverse all DOACs, is still under investigation. In this review we provide an update on the pharmacology of DOACs, the risk of hemorrhagic complications associated with their use, the measurement of their anticoagulant effect and the reversal strategies in case of DOAC-associated bleeding.
author	Enríquez,Andrés Baranchuk,Adrian Corbalán,Ramón
author_facet	Enríquez,Andrés Baranchuk,Adrian Corbalán,Ramón
author_sort	Enríquez,Andrés
title	Manejo de hemorragia asociada a anticoagulantes orales directos: estado actual de las estrategias de reversión
title_short	Manejo de hemorragia asociada a anticoagulantes orales directos: estado actual de las estrategias de reversión
title_full	Manejo de hemorragia asociada a anticoagulantes orales directos: estado actual de las estrategias de reversión
title_fullStr	Manejo de hemorragia asociada a anticoagulantes orales directos: estado actual de las estrategias de reversión
title_full_unstemmed	Manejo de hemorragia asociada a anticoagulantes orales directos: estado actual de las estrategias de reversión
title_sort	manejo de hemorragia asociada a anticoagulantes orales directos: estado actual de las estrategias de reversión
publisher	Sociedad Médica de Santiago
publishDate	2019
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000100073
work_keys_str_mv	AT enriquezandres manejodehemorragiaasociadaaanticoagulantesoralesdirectosestadoactualdelasestrategiasdereversion AT baranchukadrian manejodehemorragiaasociadaaanticoagulantesoralesdirectosestadoactualdelasestrategiasdereversion AT corbalanramon manejodehemorragiaasociadaaanticoagulantesoralesdirectosestadoactualdelasestrategiasdereversion
_version_	1718437043388809216

Manejo de hemorragia asociada a anticoagulantes orales directos: estado actual de las estrategias de reversión

Ejemplares similares